Harmony Bioscien Rg

Harmony Biosciences Holdings, Inc. is a commercial‑stage biopharma focused on rare neurological disorders. Its marketed treatment, WAKIX, treats narcolepsy, while pitolisant and other agents—Phase 3 for Prader‑Willi and Fragile X—aim to tap high‑growth unmet markets.

Headquarters: United States (USA)

Harmony Bioscien Rg Logo
Company Profile
  • Employees: 268
  • HQ: Plymouth Meeting
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
HRMY Harmony Bioscien Rg
Cap: 2.2B | P/E: 12.2
EQUITY NGM USD US4131971040 Active
📈
Home Login